GlassScriptPhysician profile
Glenn A Harris
NPI 1659478014
$2,940.70
in general payments reported to CMS, 2019-2025
22 companies · $955 in 2025
The $955 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.45 · 2022: $524 · 2023: $780 · 2024: $659 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.33 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $552.33 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $390.35 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $334.71 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $252.77 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $246.41 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $240.95 | 2023-2024 | |
| Pfizer INC. | $209.59 | 2022-2025 | |
| Boston Scientific Corporation | $154.18 | 2022-2023 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $153.79 | 2025 | Amvuttra |
| Novo Nordisk INC | $80.34 | 2022-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.43 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.21 | 2024 | Lifevest |
| Baxter Healthcare | $37.11 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $30.82 | 2022-2023 | Farxiga |
| Inspire Medical Systems, INC. | $26.05 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.07 | 2024 | Confirm Rx |
| Irhythm Technologies, INC. | $23.62 | 2022 | |
| Glaxosmithkline, LLC. | $22.45 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.26 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $19.70 | 2023 | Definity |
| Esperion Therapeutics, INC. | $18.95 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $15.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.